Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
The primary objective is to determine the noninferiority (NI) in the early clinical response rate of intravenous (IV) to oral 6 day TR-701 free acid (FA) compared with that of IV to oral 10-day linezolid treatment at 48-72 hours after the first infusion of study drug in the intent-to-treat (ITT) analysis set in patients with acute bacterial skin and skin structure infections (ABSSSI).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients requiring IV antibiotic therapy and with systemic signs of infection diagnosed with ABSSSI.
Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections
You may not be if
Uncomplicated skin infections
Severe sepsis or septic shock
ABSSSI solely due to gram-negative pathogens
Clareo Health | TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
